Priority review for Takeda’s ultra-rare blood clot ERT; FDA to give another look at Ardelyx’s CKD drug
The FDA will review Takeda’s enzyme replacement therapy for an ultra-rare blood clotting disorder and decide whether to approve it within six months, the Japanese …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
